By Adriano Marchese
Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors.
Shares traded 55% lower ahead of the morning bell at $3.51.
The clinical stage biopharmaceutical company said Friday it decided to pause the Beacon-IPF phase 2b trial of bexotegrast after a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board.
The drug is a treatment for idiopathic pulmonary fibrosis, a common type of pulmonary fibrosis which is characterized by scarring of the lungs but in particular, where the scarring is of unknown cause.
The pause means that the company won't enroll anymore patients to the study and will also halt dosing for the time being.
Pliant said that it will review the data to understand the monitoring board's rationale for their recommendation. It has also informed clinical trial investigators and is in the process of informing global regulatory authorities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 10, 2025 06:28 ET (11:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。